TickerFacts.

Autolus Therapeutics plc (AUTL): Shareholders' Equity

Annual figures by period end, from SEC filings.

$178.13M
As of 2025-12-31
$74.84M
As of 2026-06-30
-15.8%
3-year compound annual growth
-3.2%
5-year compound annual growth
$427.32M2016-09-30: $30.69M2017-09-30: $142.60M2017-12-31: $137.51M2018-09-30: $255.47M2018-12-31: $232.64M2019-12-31: $254.84M2020-12-31: $210.03M2021-12-31: $313.32M2022-03-31: $271.14M2022-06-30: $214.52M2022-09-30: $161.15M2022-12-31: $298.67M2023-03-31: $266.92M2023-06-30: $229.34M2023-09-30: $180.52M2023-12-31: $111.47M2024-12-31: $427.32M2025-12-31: $178.13M$178.13M
2016-09-30 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$178.13M-58.3%2026-03-27, Balance as of period end
2024-12-31$427.32M+283.3%2026-03-27, Balance as of period end
2023-12-31$111.47Mn/a2025-03-20, Balance as of period end
2023-09-30$180.52Mn/a2024-03-21, Balance as of period end
2023-06-30$229.34Mn/a2024-03-21, Balance as of period end
2023-03-31$266.92Mn/a2024-03-21, Balance as of period end
2022-12-31$298.67Mn/a2024-03-21, Balance as of period end
2022-09-30$161.15Mn/a2024-03-21, Balance as of period end
2022-06-30$214.52Mn/a2024-03-21, Balance as of period end
2022-03-31$271.14Mn/a2024-03-21, Balance as of period end
2021-12-31$313.32M+49.2%2024-03-21, Balance as of period end
2020-12-31$210.03M-17.6%2023-03-07, Balance as of period end
2019-12-31$254.84M+9.5%2022-03-10, Balance as of period end
2018-12-31$232.64Mn/a2021-03-04, Balance as of period end
2018-09-30$255.47Mn/a2021-03-04, Balance as of period end
2017-12-31$137.51Mn/a2019-02-25, Balance as of period end
2017-09-30$142.60M+364.7%2020-03-03, Balance as of period end
2016-09-30$30.69Mn/a2019-02-25, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Autolus Therapeutics plc (AUTL)2025-12-31$178.13M-58.3%
Recursion Pharmaceuticals, Inc. (RXRX)2025-12-31$1.13B+9.3%
Compugen Ltd (CGEN)2025-12-31$102.73M+87.1%
Black Diamond Therapeutics, Inc. (BDTX)2025-12-31$112.21M+34.7%
MeiraGTx Holdings plc (MGTX)2025-12-31-$5.79Mn/m
Vir Biotechnology, Inc. (VIR)2025-12-31$765.28M-33.5%
4D Molecular Therapeutics, Inc. (FDMT)2025-12-31$505.66M-1.0%
Champions Oncology, Inc. (CSBR)2026-04-30$3.94M+4.4%
Sutro Biopharma, Inc. (STRO)2025-12-31-$132.45Mn/m

Compare AUTL, RXRX, CGEN, BDTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗